Date	Headline
Jul 19, 2021	9 Meters Biopharma, Inc. Announces the Acquisition of Humanized Anti-GIP Monoclonal Antibody from Lobesity
Jul 8, 2021	9 Meters Biopharma, Inc. To Present at the William Blair Biotech Focus Conference
Jun 28, 2021	9 Meters Added to Russell 2000(R) and 3000(R) Indexes
Jun 14, 2021	9 Meters Announces Initiation of Phase 2 VIBRANT Study of Vurolenatide for Short Bowel Syndrome
Jun 9, 2021	9 Meters Biopharma, Inc. to Present at 2021 BIO Digital
Jun 1, 2021	9 Meters Biopharma, Inc. to Present at the Jefferies Virtual Healthcare Conference
May 26, 2021	9 Meters Biopharma, Inc. Announces Publication in Journal of Clinical Investigation Describing Successful Use of Larazotide for Treating Multisystem Inflammatory Syndrome in Children (MIS-C) resulting from COVID-19 Infection
May 18, 2021	CORRECTION 9 Meters Biopharma, Inc. to Present at Oppenheimer's Rare & Orphan Disease Summit
May 18, 2021	9 Meters Biopharma, Inc. to Present at Oppenheimer's Rare & Orphan Disease Summit
May 17, 2021	9 Meters Biopharma, Inc. Receives USAN Approval to Use the Designated Nonproprietary Name Vurolenatide for Its Long-Acting GLP-1 Agonist for Short Bowel Syndrome